2013分子向课件.ppt

* * 演讲重点：赫赛汀?作为全球第一种获准应用于临床治疗实体瘤的人源化单克隆抗体，为HER2癌基因阳性的肿瘤患者带来了新的希望. 1。1998年上市之初的临床资料即显示了赫赛汀对HER2阳性的转移性乳腺癌不仅显著改善HER2阳性患者的生存率达45%，而且疗效改善持续，维持病人生活质量。 2。2002年陆续开展了四项的赫赛汀辅助治疗的大型全球随机对照多中心临床，入组患者达13000例，基于这些临床试验的结果，欧盟和FDA于2006年批准赫赛汀辅助治疗早期乳腺癌 * * Partial response within radiation field in a patient treated with radiation and 100mg of Nimotuzumab in Arm 1. * 60 years old, man, 73% tumor reduction. * Partial response of large RUL mass to radiation and Nimotuzumab at 200mg in Arm 2: shrinkage of second mass outside the radiation field can be attributable only to Nimotuzumab. * * JCO dec 10, 2006 Other tumors mTOR Sarcomas Rabdomiosarcoma (IGF2, 4E BP1, Akt) Leiomiosarcoma ( PTEN) PECOMA ( PTEN, Akt) Sinovialsarcoma ( IGF 1R) Ewing’s Sarcoma (IGF 1R, EGF) Kaposi’s Sarcoma (TSC 1) Conclusions mTOR pathway is extremely complex mTOR, HER, KIT pathways are field of many translational researches Its involvement is well demonstrated in many tumours. No definitive biomarkers are available till now mTOR inibithors can be used alone or in combination. QQ：403491480 * 与传统化疗药物不同，靶向药物利用肿瘤细胞与正常细胞分子生物学上的差异，作用于肿瘤的一些特有的结构或与肿瘤细胞生长信号传递有关的受体，酶，蛋白等，从而有选择性的阻断，杀伤和抑制肿瘤的生长 * - The epidermal growth factor receptor (EGFR) is a transmembrane receptor with an intracellular tyrosine kinase domain, which is activated by growth factors. The main activating ligands are epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-alpha).[1] - EGFR is a proto-oncogene and its activation plays a key role in the development of many cancers.[2] Activation occurs because of gene amplification, gene mutation and/or autocrine stimulation due to the overproduction of the EGFR ligands (e.g. EGF and TGF-alpha). Activation leads to the pairing of receptors with either another EGFR (homodimers) or another member of the EGFR family (heterodimers).[1] - Receptor dimerization initiates an intracellular signaling cascade, gene activation and the stimulation of cell cycle progression.[1] 1. Baselga J. E